Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

TB prevention news

Show

From To
New TB cases occur rapidly among close contacts of people with pulmonary TB

The close contacts of people with active pulmonary tuberculosis (TB) have high rates of the disease, according to US and Canadian research published in The

Published
12 June 2018
By
Michael Carter
Hepatitis B or raised liver enzymes predict liver toxicity when TB prevention drug is combined with HIV treatment

The risk of liver toxicity in people with HIV taking antiretroviral therapy and isoniazid preventive therapy for tuberculosis is strongly associated with either hepatitis B

Published
06 June 2018
By
Michael Carter
TB Treatment May Leave Some Patients Contagious

The World Health Organization’s dosage guidelines for two leading tuberculosis medications may be far too low for patients with H.I.V., allowing them to remain contagious for longer than necessary, a new study has found.

Published
09 April 2018
From
New York Times
Isoniazid preventive therapy: do the risks outweigh the benefits in pregnant women with HIV?

Isoniazid preventive therapy (IPT) during and after pregnancy in women living with HIV on antiretroviral therapy (ART) in tuberculosis (TB) endemic areas in Africa, Asia

Published
13 March 2018
By
Carole Leach-Lemens
One-month TB prevention regimen just as effective as 9-month regimen

A one-month course of the antibiotic rifapentine combined with isoniazid was just as effective as a nine-month course of isoniazid in preventing the development of tuberculosis in people

Published
06 March 2018
By
Keith Alcorn
Zambia: HIV deaths on treatment underestimated

People with HIV in Zambia were at least ten times more likely to die in the first two years after starting antiretroviral treatment than European

Published
14 February 2018
By
Keith Alcorn
Isoniazid preventive treatment reduces the risk of death by 37% in people living with HIV

A six-month course of isoniazid preventive treatment (IPT) at the beginning of the Temprano trial in Ivory Coast reduced the risk of death by 37% over

Published
16 February 2017
By
Keith Alcorn
Latent TB high in India's healthcare workers

While India continues to have the highest burden of tuberculosis in the world, about 23 per cent of the 8.7 million global incidences, a study reports nearly half of its healthcare workers taking care of TB patients also suffer from latent tuberculosis.

Published
17 October 2016
From
SciDevNet
TB drugs may be disrupted by botanical supplement, MU researchers find

MU researchers, working with scientists in Africa, discovered that a widely used African botanical supplement called Sutherlandia — traditionally taken to prevent or treat symptoms of infections — may actually disrupt the effectiveness of a common anti-tuberculosis drug, isoniazid.

Published
11 October 2016
From
Kansas City Star
Zimbabwe study sees TB go down as HIV treatment coverage goes up

As the numbers of people accessing HIV treatment went up in Zimbabwe, the numbers of reported tuberculosis cases were cut nearly in half.

Published
06 October 2016
From
Science Speaks
← First12345...12Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.